IQVIA balance sheet
At the end of fiscal 2025, IQVIA had total assets of $29.94bn, total liabilities of $23.31bn and shareholders' equity of $6.50bn. It held $1.98bn in cash against $15.80bn of debt: net debt of $13.82bn.
Balance sheet
| Fiscal year | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 0.5 | 0.6 | 0.8 | 0.9 | 1.0 | 1.2 | 1.0 | 0.9 | 0.8 | 1.8 | 1.4 | 1.2 | 1.4 | 1.7 | 2.0 | 2.2 |
| Receivables | — | 0.7 | 0.9 | 1.0 | 1.2 | 1.7 | 2.1 | 2.4 | 2.6 | 2.4 | 2.6 | 2.9 | 3.4 | 3.2 | 3.4 | 3.3 |
| Total current assets | — | 1.5 | 1.9 | 2.1 | 2.4 | 3.3 | 3.6 | 3.9 | 4.1 | 5.1 | 4.8 | 5.0 | 5.6 | 5.8 | 6.2 | 6.5 |
| Goodwill | 0.3 | 0.3 | 0.4 | 0.5 | 0.7 | 10.7 | 11.9 | 11.8 | 12.2 | 12.7 | 13.3 | 13.9 | 14.6 | 14.7 | 16.6 | 16.9 |
| Total assets | 2.3 | 2.5 | 3.1 | 3.3 | 3.9 | 21.2 | 22.9 | 22.5 | 23.3 | 24.6 | 24.7 | 25.3 | 26.7 | 26.9 | 29.9 | 30.5 |
| Accounts payable | — | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 | 0.3 | 0.4 | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | — | 0.5 | 0.5 | 0.5 | 0.6 | 0.8 | 1.0 | 1.0 | 1.0 | 1.3 | 1.8 | 1.8 | 1.8 | 1.8 | 2.1 | 2.3 |
| Total current liabilities | — | 1.3 | 1.5 | 1.5 | 1.6 | 2.7 | 3.2 | 3.5 | 3.9 | 4.6 | 5.2 | 5.6 | 6.5 | 7.0 | 8.3 | 7.8 |
| Short-term debt | — | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.7 | 1.1 | 1.8 | 1.2 |
| Long-term debt | — | 2.4 | 2.0 | 2.3 | 2.4 | 7.1 | 10.1 | 10.9 | 11.5 | 12.4 | 12.0 | 12.6 | 13.0 | 12.8 | 13.9 | 14.8 |
| Total debt | 0.0 | 2.4 | 2.1 | 2.3 | 2.5 | 7.2 | 10.3 | 11.1 | 11.7 | 12.6 | 12.2 | 12.8 | 13.8 | 14.0 | 15.8 | 16.2 |
| Total liabilities | — | 3.9 | 3.7 | 4.0 | 4.3 | 12.3 | 14.6 | 15.6 | 17.0 | 18.3 | 18.6 | 19.6 | 20.6 | 20.8 | 23.3 | 23.7 |
| Shareholders' equity | −1.0 | −1.4 | −0.7 | −0.7 | −0.6 | 8.6 | 8.0 | 6.7 | 6.0 | 6.0 | 6.0 | 5.8 | 6.1 | 6.1 | 6.5 | 6.7 |
| Non-controlling interests and other (assets − liabilities − equity) | — | — | — | — | 0.2 | — | — | — | — | — | — | — | — | — | — | — |
| Net debt (negative = net cash) | −0.5 | 1.9 | 1.3 | 1.4 | 1.5 | 6.0 | 9.3 | 10.2 | 10.9 | 10.8 | 10.8 | 11.6 | 12.4 | 12.3 | 13.8 | 13.9 |
| Shares outstanding | 116m | 116m | 130m | 124m | 119m | — | — | 198m | 192m | 191m | 191m | 186m | 182m | 176m | 170m | 165m |
| Quarter | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 | 2026 Q3Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Receivables | 3.2 | 3.3 | 3.3 | 3.3 | 3.4 | 3.3 | 3.3 | 3.3 |
| Total current assets | 5.8 | 5.9 | 6.3 | 6.0 | 6.2 | 6.2 | 6.2 | 6.5 |
| Goodwill | 14.7 | 15.0 | 15.6 | 15.9 | 16.6 | 16.5 | 16.6 | 16.9 |
| Total assets | 26.9 | 27.3 | 28.6 | 28.7 | 29.9 | 29.7 | 29.9 | 30.5 |
| Deferred revenue (current) | 1.8 | 1.9 | 2.1 | 2.2 | 2.1 | 2.3 | 2.3 | 2.3 |
| Total current liabilities | 7.0 | 7.2 | 7.6 | 8.5 | 8.3 | 8.3 | 8.8 | 7.8 |
| Short-term debt | 1.1 | 1.2 | 1.3 | 2.2 | 1.8 | 1.8 | 2.3 | 1.2 |
| Long-term debt | 12.8 | 13.1 | 14.2 | 12.8 | 13.9 | 14.0 | 13.7 | 14.8 |
| Total debt | 14.0 | 14.3 | 15.5 | 15.0 | 15.7 | 15.8 | 16.0 | 16.1 |
| Total liabilities | 20.8 | 21.3 | 22.8 | 22.4 | 23.3 | 23.3 | 23.6 | 23.7 |
| Shareholders' equity | 6.1 | 6.0 | 5.8 | 6.2 | 6.5 | 6.2 | 6.2 | 6.7 |
| Shares outstanding | 176m | 174m | 170m | 170m | 170m | 167m | 165m | 165m |
Compare with peers
- Danaher Corporation balance sheet
- Icon PLC balance sheet
- Agilent Technologies balance sheet
- Avantor, Inc. balance sheet
- Thermo Fisher Scientific balance sheet
Head to head: DHR vs IQVICLR vs IQVA vs IQVIQV vs TMO
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies